FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 99 filers reported holding FIVE PRIME THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $6,089,000 | +102.2% | 358,021 | -44.1% | 0.02% | +84.6% |
| Q3 2020 | $3,011,000 | -7.2% | 640,560 | +20.5% | 0.01% | -7.1% |
| Q2 2020 | $3,243,000 | +235.4% | 531,608 | +24.8% | 0.01% | +133.3% |
| Q1 2020 | $967,000 | -16.0% | 425,862 | +70.0% | 0.01% | +20.0% |
| Q4 2019 | $1,151,000 | +89.9% | 250,463 | +60.3% | 0.01% | +66.7% |
| Q3 2019 | $606,000 | -30.0% | 156,221 | +8.9% | 0.00% | -25.0% |
| Q2 2019 | $866,000 | -25.2% | 143,508 | +66.0% | 0.00% | -20.0% |
| Q1 2019 | $1,158,000 | -87.2% | 86,430 | -65.4% | 0.01% | -87.8% |
| Q1 2017 | $9,035,000 | -82.7% | 249,909 | -76.0% | 0.04% | -83.9% |
| Q4 2016 | $52,235,000 | -10.5% | 1,042,389 | -6.2% | 0.25% | -12.1% |
| Q3 2016 | $58,332,000 | +28.9% | 1,111,332 | +1.6% | 0.29% | +25.1% |
| Q2 2016 | $45,250,000 | +115.8% | 1,094,368 | +112.1% | 0.23% | +117.9% |
| Q1 2016 | $20,966,000 | +110247.4% | 515,957 | +61914.1% | 0.11% | – |
| Q1 2015 | $19,000 | – | 832 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 115,500 | $2,531,000 | 0.89% |
| AWM Investment Company, Inc. | 150,000 | $3,288,000 | 0.64% |
| BB BIOTECH AG | 827,500 | $18,139,000 | 0.51% |
| Virtus ETF Advisers LLC | 17,371 | $381,000 | 0.48% |
| Rock Springs Capital Management LP | 425,000 | $9,316,000 | 0.42% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 450,728 | $9,880,000 | 0.39% |
| Telemetry Investments, L.L.C. | 44,176 | $968,000 | 0.37% |
| RTW INVESTMENTS, LP | 100,377 | $2,200,000 | 0.37% |
| Eventide Asset Management | 315,000 | $6,905,000 | 0.36% |
| ACUTA CAPITAL PARTNERS, LLC | 52,500 | $1,151,000 | 0.22% |